Drug development and research business by using MRI and PET

Overview

We are Japan’s first CRO utilizing experimental MRI and PET contributing to saving time, reduction in cost and the number of laboratory animals by making good use of our experience and expertise in pharmacological imaging as below, and also conducts MRI-safety evaluation.

Consulting Service, Safety Management Service, Post-Marketing Pharmaceutical Service

Overview

Support resolving company’s problems with broad services.
1. Consulting Service
・Advise and interview support for responding inquiry matters to authorities
・Support obtaining and renewing the authorization of manufacturing and distribution
2. Safety Management Service
・Accept whole medicine and medical device’s safety management operation
3. Post-Marketing Pharmaceutical Service
・Construct package insert and related documents
・CMC pharmaceutical operation

Designing and creating instructions for medical devices

Overview

Electrosuisse Japan Started the business at Kobe in January 2007.
Electrosuisse Japan conducts support services for instruction manuals for medical devices, etc. against the background of its extensive track record which comprise designing, producing and translating, as well as consulting, etc. for risk analysis which is based upon usage environments and user perspectives, and performing usability tests, and complying with ISO standards and standards, etc.
In addition, Electrosuisse Japan is carrying out gap analysis and adaptation measures technical support to incorporate the viewpoint of risk and benefit communication, which USFDA is focusing on in recent years, into documents for medical equipments and documents for medical facilities.

Strategic investment in venture companies engaged in research and development of pharmaceuticals and medical devices

Overview

We are actively investing in venture companies engaged in the research and development of pharmaceuticals and medical devices. We are committed to supporting the growth of venture companies and academia, which have limited funds, to enhance their value. In addition, the Gemseki Division of our parent company, Shin Nippon Biomedical Laboratories (SNBL), provides strong support for partnership-building and licensing activities that are essential for the promotion of these businesses. We and Gemseki Division will contribute to the advancement of medical care by providing a one-stop service for the creation of innovative drugs and medical devices as SNBL Group.

Conducting a consulting business in the field of medicine

Regulatory consultation and clinical development service for Cell and Gene Therapy (CAGT), innovative pharmaceutical product and medical device

Overview

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry dedicated to creating intelligent connections that deliver unique and actionable insights. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.

R&D assistance and evaluation of medical equipment

Overview

In a wide range of fields from the nano region to large-scale structures, we provide high reliability analysis and evaluation technologies using state-of-the-art analysis and testing equipment. Our technical staff of 500 experts possesses a wealth of experience, and is ready to assist clients in solving technical problems in all aspects of “monodzukuri” : such as stabilization of product quality, added functions, and reduction of production costs.